| Primary |
| Atrial Fibrillation |
27.9% |
| Product Used For Unknown Indication |
15.4% |
| Drug Use For Unknown Indication |
12.1% |
| Ventricular Tachycardia |
9.0% |
| Arrhythmia |
6.1% |
| Hypertension |
5.7% |
| Atrial Flutter |
3.1% |
| Cardiovascular Disorder |
3.1% |
| Ventricular Fibrillation |
2.7% |
| Supraventricular Tachycardia |
2.1% |
| Pain |
1.7% |
| Cardiovascular Event Prophylaxis |
1.5% |
| Tachycardia |
1.5% |
| Arrhythmia Prophylaxis |
1.4% |
| Tachyarrhythmia |
1.2% |
| Arrhythmia Supraventricular |
1.1% |
| Cardiac Disorder |
1.1% |
| Cardiomyopathy |
1.1% |
| Prophylaxis |
1.1% |
| Anaesthesia |
1.0% |
|
| Toxicity To Various Agents |
11.7% |
| Ventricular Tachycardia |
11.2% |
| Torsade De Pointes |
8.5% |
| Hyperthyroidism |
5.9% |
| International Normalised Ratio Increased |
5.3% |
| Pulmonary Fibrosis |
5.3% |
| Thrombophlebitis |
5.3% |
| Vomiting |
5.3% |
| Weight Decreased |
4.8% |
| Lymphoid Tissue Hyperplasia |
4.3% |
| Interstitial Lung Disease |
3.7% |
| Pulmonary Toxicity |
3.7% |
| Hepatorenal Syndrome |
3.2% |
| Hyponatraemia |
3.2% |
| Hypotension |
3.2% |
| Transaminases Increased |
3.2% |
| Tremor |
3.2% |
| Venous Thrombosis Limb |
3.2% |
| Visual Impairment |
3.2% |
| Epistaxis |
2.7% |
|
| Secondary |
| Product Used For Unknown Indication |
28.0% |
| Atrial Fibrillation |
14.2% |
| Drug Use For Unknown Indication |
11.5% |
| Ventricular Tachycardia |
8.4% |
| Drug Abuse |
7.8% |
| Arrhythmia |
4.3% |
| Supraventricular Tachycardia |
3.8% |
| Hypertension |
3.1% |
| Myocardial Ischaemia |
2.9% |
| Atrial Flutter |
2.6% |
| Ventricular Fibrillation |
2.1% |
| Pneumonia |
1.9% |
| Chronic Obstructive Pulmonary Disease |
1.6% |
| Tachycardia Foetal |
1.6% |
| Prophylaxis |
1.2% |
| Pain |
1.1% |
| Cardiac Failure |
1.1% |
| Cardiac Failure Congestive |
1.1% |
| Unevaluable Event |
1.0% |
| Left Ventricular Dysfunction |
1.0% |
|
| Ventricular Tachycardia |
26.6% |
| Torsade De Pointes |
7.7% |
| Rhabdomyolysis |
6.9% |
| Talipes |
6.0% |
| Thrombophlebitis |
5.4% |
| Pulmonary Embolism |
4.6% |
| Syncope |
4.3% |
| Vomiting |
4.0% |
| Renal Failure Acute |
3.7% |
| Supraventricular Tachycardia |
3.7% |
| Respiratory Failure |
3.4% |
| Toxicity To Various Agents |
3.4% |
| Myositis |
3.2% |
| International Normalised Ratio Increased |
2.9% |
| Pulmonary Toxicity |
2.9% |
| Paraesthesia |
2.6% |
| Completed Suicide |
2.3% |
| Pulmonary Fibrosis |
2.3% |
| Medication Error |
2.0% |
| Renal Failure |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
42.7% |
| Drug Use For Unknown Indication |
20.3% |
| Atrial Fibrillation |
9.0% |
| Hypertension |
6.0% |
| Cardiac Disorder |
2.2% |
| Pain |
2.1% |
| Arrhythmia |
1.8% |
| Diabetes Mellitus |
1.7% |
| Prophylaxis |
1.6% |
| Cardiac Failure |
1.5% |
| Blood Cholesterol Increased |
1.5% |
| Cerebrovascular Accident Prophylaxis |
1.3% |
| Coronary Artery Bypass |
1.2% |
| Anticoagulant Therapy |
1.2% |
| Multiple Myeloma |
1.2% |
| Sedation |
1.1% |
| Chronic Obstructive Pulmonary Disease |
1.0% |
| Depression |
0.9% |
| Hypothyroidism |
0.9% |
| Cardiac Failure Congestive |
0.8% |
|
| Vomiting |
13.4% |
| Weight Decreased |
10.4% |
| Ventricular Tachycardia |
7.5% |
| Renal Failure Acute |
6.9% |
| Death |
5.6% |
| Weight Increased |
5.3% |
| Thrombocytopenia |
5.2% |
| Renal Failure |
4.6% |
| Sepsis |
4.1% |
| Urinary Tract Infection |
4.1% |
| Pneumonia |
3.9% |
| International Normalised Ratio Increased |
3.8% |
| Gastrointestinal Haemorrhage |
3.5% |
| Pain |
3.5% |
| Syncope |
3.3% |
| Ventricular Fibrillation |
3.2% |
| Unevaluable Event |
3.1% |
| Injury |
2.8% |
| Atrial Fibrillation |
2.8% |
| Dyspnoea |
2.8% |
|
| Interacting |
| Drug Use For Unknown Indication |
18.1% |
| Product Used For Unknown Indication |
15.8% |
| Atrial Fibrillation |
15.1% |
| Myocardial Ischaemia |
8.1% |
| Supraventricular Tachycardia |
8.1% |
| Lower Respiratory Tract Infection |
6.7% |
| Pneumonia |
6.4% |
| Atrial Tachycardia |
3.4% |
| Sinus Arrhythmia |
2.8% |
| Hiv Infection |
2.6% |
| Prophylaxis |
2.1% |
| Hypertension |
1.7% |
| Chronic Obstructive Pulmonary Disease |
1.5% |
| Ventricular Fibrillation |
1.4% |
| Cerebrovascular Accident Prophylaxis |
1.2% |
| Pain |
1.2% |
| Insomnia |
1.0% |
| Prostate Cancer |
1.0% |
| Arrhythmia |
0.9% |
| Ill-defined Disorder |
0.9% |
|
| Supraventricular Tachycardia |
19.4% |
| Torsade De Pointes |
10.7% |
| Rhabdomyolysis |
8.7% |
| Drug Interaction |
7.8% |
| Electrocardiogram Qt Prolonged |
6.8% |
| Upper Gastrointestinal Haemorrhage |
5.8% |
| Ventricular Tachycardia |
5.8% |
| Toxicity To Various Agents |
4.9% |
| Myositis |
3.9% |
| Renal Failure Acute |
3.9% |
| Ventricular Fibrillation |
3.9% |
| International Normalised Ratio Increased |
2.9% |
| Electrocardiogram Qrs Complex Prolonged |
1.9% |
| Hypocoagulable State |
1.9% |
| International Normalised Ratio Abnormal |
1.9% |
| Pneumonia |
1.9% |
| Prothrombin Time Shortened |
1.9% |
| Sinus Bradycardia |
1.9% |
| Syncope |
1.9% |
| Vomiting |
1.9% |
|
